Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- AI Companion Tool Identifies Food Triggers Based on IBS Sensitivity Testing (CLP)
- British startup BoobyBiome raises €2.8 million for infant health with breast milk microbiome breakthrough (EU-Startups)
- Locum tenens: Reclaiming purpose, autonomy, and financial freedom in medicine (KevinMD)
- Getting Ahead of Gastrointestinal Cancer (Medscape)
- Can AI and Molecular Testing Outperform Colonoscopy? (The Pathologist)
- Precision Gastroenterology: Harnessing Personalized Medicine for Transformative Patient Care (ASGE)
- Transforming Colonoscopy: The Role of Mechanical Enhancements in Boosting Polyp Detection Rates (ReachMD)
- Health Insurance Premiums To Rise Well Above Inflation For Most Americans (Forbes)